AGIO - NASDAQ

Agios Pharmaceuticals, Inc.

AGIO·NASDAQ

$27.68

-1.1%

HealthcareBiotechnology

Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and AG-946 that is in Phase I clinical study for treating hemolytic anemias and other indications. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$1.65B

EPS-7.1200

P/E Ratio-3.89

Earnings Date07/30/2026

1.30B

Assets

-22%

3Y+5.0%

5Y+52.0%

10Y+110.0%

104.11M

Total Liabilities

-15%

3Y-25.0%

5Y-77.0%

10Y-60.0%

1.19B

Total Equity

-23%

3Y+8.0%

5Y+199.0%

10Y+233.0%

Agios Pharmaceuticals, Inc. Funding & Solvency Profile

AGIO · NASDAQ

Current Assets

Cash & Cash Equivalents89.13M

Net Receivables10.58M

Inventory32.92M

Other Current Assets44.13M

Total Current Assets942 M

Non-Current Assets

Property, Plant & Equipment41.23M

Goodwill & Intangible Assets0.00

Long-Term Investments310.01M

Other Non-Current Assets3.93M

Total Non-Current Assets355 M

Total Assets

1.30B

Financial Health Analysis

Current Ratio

11.46x

Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.

Debt-to-Equity Ratio

0.09x

Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.

Working Capital

860 M

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

73% Current

Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.

Financial Health Insight

Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.

Agios Pharmaceuticals, Inc. Balance Sheet

AGIO • NASDAQ

Agios Pharmaceuticals, Inc. Balance Sheet	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018	Dec 2017	Dec 2016	Dec 2015	Dec 2014	Dec 2013	Dec 2012	Dec 2011
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	89.1M	76.2M	88.2M	139.3M	203.1M	127.4M	80.9M	805.4M	567.8M	573.6M	375.9M	14M	71.6M	91.3M	117.7M
Short-Term Investments	765.3M	817.5M	688.7M	643.9M	816.9M	445.5M	483.9M	0.0	0.0	0.0	0.0	328M	95.2M	36.7M	61.5M
Cash & Short-Term Investments	854.4M	893.7M	776.9M	783.1M	1B	572.9M	564.9M	805.4M	567.8M	573.6M	375.9M	342.1M	166.8M	128M	179.2M
Net Receivables	10.6M	4.1M	2.8M	2.2M	4.4M	0.0	15.3M	10.4M	3.7M	8.3M	11.6M	12.7M	476K	0.0	0.0
Accounts Receivables	10.6M	4.1M	2.8M	2.2M	0.0	23.5M	15.3M	10.4M	3.7M	4.9M	8.2M	6.5M	476K	0.0	0.0
Other Receivables	0.0	0.0	0.0	0.0	4.4M	-23.5M	0.0	0.0	0.0	3.4M	3.4M	2.3M	0.0	0.0	0.0
Inventory	32.9M	27.6M	19.1M	8.5M	0.0	0.0	7.3M	869K	-143.8M	-32.3M	-58.9M	0.0	0.0	0.0	0.0
Prepaids	0.0	0.0	0.0	0.0	39.8M	0.0	24.2M	17.2M	17.7M	10.3M	8.7M	4.8M	2.5M	922K	794K
Other Current Assets	44.1M	40.2M	35M	39M	0.0	63.7M	0.0	17.2M	0.0	0.0	0.0	0.0	0.0	1.2M	10.6M
Total Current Assets	942.1M	965.6M	833.8M	832.8M	1.1B	636.7M	611.7M	613.8M	445.3M	559.9M	337.3M	359.5M	169.7M	130.1M	190.6M
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	41.2M	54.6M	69.8M	88.1M	104.2M	116.1M	126.1M	24.3M	24.4M	25.3M	23.2M	6.4M	3.8M	3.6M	3.2M
Long-Term Investments	310M	638.3M	29.4M	313.9M	266.4M	97.6M	152.9M	220.1M	143.8M	32.3M	58.9M	125.4M	27.1M	0.0	0.0
Tax Assets	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.7M	37K
Other Non-Current Assets	3.9M	4.7M	4.1M	4M	2.9M	2.6M	0.0	238K	891K	1.6M	611K	590K	575K	593K	626K
Total Non-Current Assets	355.2M	697.6M	103.3M	405.9M	373.5M	216.3M	279M	244.7M	169.1M	59.2M	82.7M	132.4M	31.5M	6.9M	3.9M
Total Assets	1.3B	1.7B	937.1M	1.2B	1.4B	853M	890.7M	858.5M	614.4M	619.1M	420.1M	491.9M	201.2M	137M	194.5M
LIABILITIES
CURRENT LIABILITIES
Total Payables	18.4M	17.5M	9.8M	18.6M	16.7M	17.7M	21.9M	17.9M	22.8M	17.1M	14.7M	11.1M	5.1M	8.2M	21.4M
Accounts Payable	18.4M	16.6M	9.8M	18.6M	16.7M	17.7M	21.9M	17.9M	22.8M	17.1M	14.7M	11.1M	3.7M	3.3M	3.6M
Other Payables	0.0	871K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.5M	4.9M	17.9M
Accrued Expenses	27.3M	0.0	19.9M	18.1M	12.1M	20.3M	19M	20.8M	15.7M	11.1M	7M	8.3M	2.9M	584K	979K
Short Term Debt	18.4M	0.0	0.0	0.0	0.0	7.4M	6.9M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Capital Lease Obligations (Current)	0.0	16.8M	15M	13.7M	11.2M	0.0	6.9M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Tax Payables	0.0	871K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.8M	1.5M	4.9M	17.9M
Deferred Revenue	0.0	0.0	0.0	0.0	0.0	0.0	10.9M	92.5M	163.6M	190.2M	24.4M	35.7M	25.1M	25.1M	25.1M
Other Current Liabilities	18.2M	46.9M	23.2M	12.2M	19.8M	48.9M	27.2M	22.1M	18.6M	24.3M	11.5M	6M	3.8M	1.3M	621K
Total Current Liabilities	82.2M	81.2M	68M	62.6M	59.8M	94.4M	92.9M	93.5M	94.9M	88.4M	52.9M	61.1M	36.9M	35.1M	48.2M
NON-CURRENT LIABILITIES
Long Term Debt	21.8M	0.0	0.0	0.0	0.0	0.0	106.7M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Deferred Revenue (Non-Current)	0.0	0.0	0.0	0.0	0.0	0.0	50.6M	59.8M	125.8M	154.3M	4.7M	2.7M	32.6M	57.6M	82.7M
Deferred Tax Liabilities (Non-Current)	0.0	0.0	0.0	0.0	0.0	0.0	-50.6M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other Non-Current Liabilities	-21.7M	880K	1.2M	3.3M	0.0	261.3M	-106.7M	17.6M	18.2M	17.8M	17.4M	3.7M	226K	358K	33K
Total Non-Current Liabilities	21.9M	41.1M	58.1M	75.3M	85.9M	359.1M	157.3M	77.4M	144M	172.1M	22.1M	6.4M	32.8M	58M	83.2M
Capital Lease Obligations	21.8M	57M	72M	85.7M	97.1M	97.8M	113.7M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total Liabilities	104.1M	122.2M	126.1M	137.9M	145.8M	453.5M	250.2M	170.9M	238.9M	260.5M	74.9M	67.5M	69.7M	93.1M	131.3M
SHAREHOLDERS' EQUITY
Treasury Stock	-802.5M	-802.5M	-802.5M	-802.5M	-802.5M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Preferred Stock	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	115.9M	115.9M
Common Stock	75K	73K	72K	71K	71K	69K	68K	58K	49K	42K	38K	37K	31K	3K	3K
Additional Paid-In Capital	2.6B	2.5B	2.4B	2.4B	2.3B	2.2B	2.2B	1.8B	1.2B	842M	630.1M	591.3M	244.9M	2M	1.1M
Retained Earnings	-561.7M	-148.9M	-822.6M	-470.6M	-238.8M	-1.8B	-1.5B	-1.1B	-798.1M	-483.2M	-284.7M	-166.9M	-113.4M	-74M	-53.9M
Accumulated Other Comprehensive Income/Loss	2.2M	-1.5M	-441K	-12.5M	-1.2M	105K	202K	-2.2M	-1.4M	-313K	-318K	-57K	14K	-2K	23K
Total Stockholders' Equity	1.2B	1.5B	811M	1.1B	1.3B	399.5M	640.5M	687.5M	375.5M	358.6M	345.1M	424.4M	131.5M	43.9M	63.1M
Total Equity	1.2B	1.5B	811M	1.1B	1.3B	399.5M	640.5M	687.5M	375.5M	358.6M	345.1M	424.4M	131.5M	43.9M	63.1M
SUMMARY
Total Liabilities & Equity	1.3B	1.7B	937.1M	1.2B	1.4B	853M	890.7M	858.5M	614.4M	619.1M	420.1M	491.9M	201.2M	137M	194.5M
Total Investments	1.1B	1.5B	718.2M	957.7M	1.1B	543.1M	636.9M	220.1M	143.8M	32.3M	58.9M	453.4M	122.3M	36.7M	61.5M
Total Debt	62M	57M	72M	85.7M	97.1M	105.2M	113.7M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Net Debt	-27.1M	-19.3M	-16.2M	-53.6M	-106M	-22.2M	32.7M	-805.4M	-567.8M	-573.6M	-375.9M	-14M	-71.6M	-91.3M	-117.7M
Shares Outstanding	58,313,811	58,313,811	58,313,811	58,313,811	58,313,811	58,313,811	58,313,811	58,313,811	58,313,811	58,313,811	58,313,811	58,313,811	58,313,811	58,313,811	58,313,811

SEC Filings

AGIO - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
10-Q 10-Q 2026 Q1 Q1	April 29, 2026	March 31, 2026	2026	View Filing
8-K 8-K 2026 N/A	April 29, 2026	April 29, 2026	2026	View Filing
DEF 14A DEF 14A 2026 N/A	April 24, 2026	June 18, 2026	2026	View Filing
10-K 10-K 2025 FY FY	February 12, 2026	December 31, 2025	2025	View Filing
8-K 8-K 2026 N/A	February 12, 2026	February 12, 2026	2026	View Filing
8-K 8-K 2026 N/A	January 12, 2026	January 12, 2026	2026	View Filing
10-Q 10-Q 2025 Q3 Q3	October 30, 2025	September 30, 2025	2025	View Filing
8-K 8-K 2025 N/A	October 30, 2025	October 30, 2025	2025	View Filing
8-K 8-K 2025 N/A	August 04, 2025	August 04, 2025	2025	View Filing
10-Q 10-Q 2025 Q2 Q2	July 31, 2025	June 30, 2025	2025	View Filing

Showing 1 to 10 of 261 filings

Related Guides

Blog Categories

Continue your AGIO research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.